Companies & Sectors
CCEA clears GlaxoSmithKline's Rs6,400 crore FDI proposal

After the purchase, promoter group holding in GlaxoSmithKline Pharmaceuticals will go up to 75% from the current 50.67% stake

 

The Indian government on Thursday cleared a foreign direct investment (FDI) proposal worth Rs6,400 crore of healthcare company GlaxoSmithKline to acquire additional 24.33% stake in its India unit.

 

The Cabinet Committee on Economic Affairs (CCEA) approved the proposal of Singapore-based GlaxoSmithKline Pte Ltd for acquisition of 24.33% shares in its existing Indian subsidiary GlaxoSmithKline Pharmaceuticals.

 

The said acquisition "would be done by way of a voluntary open offer under SEBI (SAST Regulations) in the pharmaceutical sector," an official statement said.

 

"The approval would result in foreign investment of approximately Rs6,390 crore in the country," the statement added.

 

GlaxoSmithKline Pharmaceuticals is already majority owned and controlled by the GSK Group.

 

After the purchase, holding of the promoter group firm in the Indian subsidiary will go up to 75% from the current level of 50.67%.

 

GSK Pharma makes, distributes and trades in a variety of drugs. Its portfolio include prescription medicines and vaccines across areas such as anti-infectives, dermatology, and gynaecology.

 

The company employs more than 5,000 people and generated more than Rs2,600 crore turnover during the financial year ended 31 December 2012.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MSSN: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)